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Secondary anti-hapten  antibody  responses to  hapten~:arrier  conjugates  generally 
display a high degree of carrier specificity (1-3). Thus, guinea  pigs  primed with 2,4- 
dinitrophenyl-ovalbumin  (DNP-OVA) 1 display  a  considerable anamnestic anti-DNP 
antibody response as a  result of challenge with DNP-OVA, but little or  no response 
to DNP conjugates of unrelated proteins  (4). 
Recently,  we  have  demonstrated  that  independent  sensitization  of  DNP-OVA- 
primed  guinea  pigs  with  bovine  gamma globulin  (BGG)  prepares  the  animals  for 
secondary  anti-DNP  antibody .responses  to  DNP-BGG  (4).  Further,  transfer  of 
lymphoid  cells  from  BGG-primed  animals  into  syngeneic  DNP-OVA-sensitized 
recipients  enables  the recipients to respond  to  DNP-BGG  (5).  These  experiments, 
together with similar data in related systems (6-9), indicate that the antigen-mediated 
stimulation of the precursors of hapten-specific antibody-forming cells is considerably 
enhanced  by  an  expanded  population  of  carrier-specific  cells  and  that  the  carrier 
specificity usually observed is explicable by the interactions of two cells and antigen, 
one of these cells being primarily specific for the carrier or the hapten-carrier complex. 
We have further shown that the function of the "carrier-specific" cell (or helper cell) 
is radiation resistant (10). 
In  the  current  studies,  we  report  that  immunocompetent  lymphoid  cells 
from  allogeneic  donor  guinea  pigs  stimulate  a  considerable  synthesis  of  anti- 
DNP and anti-OVA antibodies by recipients previously primed with DNP-OVA, 
in the absence of any further antigenic challenge, eliciting thereby a nonspecific 
anamnestic  response.  In addition,  the  transfer of such allogeneic  cells prepares 
DNP-OVA-primed  recipients, when challenged  at a suitable time, for a second- 
1  Abbreviations used in this paper: ABC, antigen-binding  capacity; BGG,  bovine gamma 
globulin;  CFA, complete  Freund's adjuvant; DNP-OVA, dinitrophenyl-ovalbumin;  GPGG, 
guinea pig gamma globulin; L~C, transplantable leukemia cells of strain 2 guinea pigs; PBS, 
phosphate-buffered  saline. 
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ary anti-DNP response to I)NP-BGG; this occurs in an equal degree whether 
or not the cells are derived from BGG-primed donors.  Thus,  the activity of 
nonspecific allogeneic immunocompetent cells (allogeneic effect)  replaces very 
adequately the  contribution of carrier-specific syngeneic cells in the stimula- 
tion of anti-hapten antibody synthesis and obviates the need for carrier specific- 
ity in anti-hapten secondary responses. 
On the basis of the failure of irradiated strain 2  guinea pig lymphoid cells, 
of  strain 2  leukemia cells,  and  of  lymphoid cells from  (2  X  13)  F1 hybrids 
to mediate this effect in strain 13 guinea pig recipients, it appears that  the ef- 
fect of allogeneic cells is related  to  a  graft-versus-host  response.  The  analysis 
of  the phenomena described  in  this study may further our understanding of 
the requirements for stimulation of precursors of antibody-forming cells,  and 
of the mechanism of cooperation between distinct classes of lymphoid cells in 
antibody responses. 
Materials and Methods 
In general, the proteins and other reagents used here are identical with those described in 
the first paper of this series (4). The following DNP conjugates were employed: I)NPT-OVA, 
I)NPm-BGG, and DNP~-BGG.  Subscripts refer to the average number of moles of I)NP/ 
mole of protein. 
Immunizations.-- 
Adult inbred strain 2 and strain 13 guinea pigs weighing 250-400 g were obtained from the 
Animal Production Section, National Institutes of Health, Bethesda, Md. Primary immuniza- 
tion of recipients was carried out with 1.0 mg of I)NPT-OVA  in saline, intraperitoneally, on 
3 successive  days. Cell donors were immunized in the footpads with 50/zg of BGG emulsified 
in complete Freund's adjuvant (CFA, Difco Laboratories,  Detroit,  Mich.)  or with saline 
emulsified  in CFA. 1.0 mg of I)NP-B GG in saline was used for secondary challenge of recipient 
guinea pigs. This was administered as a 200 #g intradermal dose followed 4 hr later by an 800 
/zg intraperitoneal dose. In the case of strain 13 recipients, dlphenhydramine hydrochloride 
(Benadryl, Parke, Davis  & Co., Detroit,  Mich.), 5.0 mg/kg, was administered intramuscu- 
larly 1 hr before the intraperitoneal  dose of DNP-BGG as a prophylactic measure against 
anaphylaxis. Animals were bled just before the secondary challenge and 4, 7, and 11 days later; 
antibody determinations were performed as described below. 
Antibody Measurements.- 
Measurement of anti-DNP antibodies: Serum anti-DNP antibody levels were determined 
by a modified Farr assay (11) using 3H-i)NP-epsilon-amino-/V-caproic  acid (12). Using stand- 
ard  curves  constructed  as described previously  (4), percentage of  binding was  converted 
into amount of anti-i)NP antibody in micrograms per milliliter. 
Measurement of anti-BGG antibodies: Quantitative determination of precipitating anti-B GG 
antibody was performed with 125I-BGG (4). In this assay, the antigen concentration at which 
50% of added antigen  (0.1 ml) was precipitated  by 0.2 ml of serum was determined  (]?5o). 
P50 is expressed as micrograms of BGG added per milliliter of antiserum. 
Measurement of anti-OVA antibodies: Serum anti-OVA antibody levels were determined by 
the Farr technique  (11) using 125I-OVA. Antigen-binding capacities (ABC-33) were deter- 
mined on the basis of the serum dilution required to bind 33% of a sample of 125I-OVA (6 
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Measurement of Total Serum Gamma Globulin.- 
Total  serum gamma globulin concentration  was  determined  by quantitative precipitin 
analysis in the following manner: 50 #1 of rabbit anti-guinea pig gamma globulin (GPGG) 
(4.85 mg/ml, kindly provided by Dr. Joseph Davie) was reacted with 5-100 #g of GPGG in 
50 #1.  Reaction mixtures were incubated at 37°C  for 1 hr and  then held at 4°C for 24 hr. 
Washed specific precipitates were dissolved in 0.02 ~  sodium lauryl sulfate and absorbancies 
at 278 m/z were determined. A standard  curve was constructed plotting absorbancy against 
amount of antigen added. This curve was log linear in the range between 5 and 30 #g of added 
GPGG and was quite reproducible from assay to assay.  Antisera to be analyzed for total 
gamma globulin concentration were diluted 1: 40-1: 80 with PBS. Utilizing the standard curve, 
the amount of gamma globulin precipitated by both serum dilutions was calculated. These 
values were then converted to milligrams of gamma globulin per milliliter of serum. Both 
of the dilutions chosen fell within the log-linear portion of the standard curve in almost every 
case.  Calculated serum concentrations based upon the two dilutions agreed very closely and 
the mean value is presented. 
Cell Transfers.- 
Donor guinea pigs were immunized in the footpads with either saline in CFA (CFA cells) 
or with 50/zg of BGG emulsified  in CFA (BGG cells). 3 wk later, the animals were sacrificed 
and axiUary, occipital, inguinal, and popliteal lymph nodes and spleens were removed. Single 
cell suspensions  in Eagle's minimum essential medium were prepared  and  washed. In each 
experiment, cell suspensions  from BGG cell donors and  CFA cell donors were pooled sepa- 
rately. Varying numbers of nucleated cells were transferred intravenously to recipient guinea 
pigs which had been immunized 3 wk earlier with DNP~-OVA as described above. 
Irradiation of Calls.- 
Single cell suspensions  received a total of 3000 R from two opposing 250 kvp Westinghouse 
X-ray tubes 25 cm apart. Each had inherent filtration of 0.25  mm Cu +  0.55 mm A1. (half- 
layer value =  0.91  mm Cu). They were operated at 200 kvp, 15 ma, and gave a combined 
dose rate of 674 R/rain to cells midway between the tubes. 
Statistical Analyses.- 
Serum antibody values were logarithmically transformed and means and standard  errors 
calculated. Results from groups were compared by Student's t test. 
RESULTS 
Stimulation of Antibody Production as a Result of Transfer of Immunocompe- 
tent Strain 2 Cells into _Primed Strain 13 Recipients (Allogeneic Effect).-- 
In the absence of secondary antigen challenge: The transfer of 200 X  l0 s lymph 
node and spleen cells from strain 2 guinea pigs, which had been immunized 3 wk 
before with  either BGG  in  CFA  or  CFA only,  into DNP-OVA-primed  strain 
13  recipients  resulted  in  the production  of considerable  amounts  of anti-DNP 
and  anti-OVA  antibodies,  although  no  challenge  with  DNP-conjugate  was 
administered.  As  shown  in  Fig.  1,  a  very sharp  increase  in  serum  anti-DNP 
antibody  concentration  occurred  between  6  and  10  days  after  the  transfer  of 
allogeneic cells. The peak concentration was noted on day 13, and by day 17 the 
serum anti-DNP  antibody concentration had diminished. The mean magnitude 
of  this  increase  was  154.0  #g/ml  in  guinea pigs whose mean  serum  anti-DNP 172  STIMULATION OF  2  °  ANTIBODY  SYNTHESIS  BY  G-V-H  RX 
antibody concentration was 19.4 #g/ml immediately after cell transfer. A com- 
parable rise was noted in anti-OVA antibodies in these recipients. By contrast, 
the increase in total gamma globulin concentration was only 1.6 mg/ml from an 
initial mean value of 6.2 mg/ml. Thus, a  marked increase in the ratios of con- 
centrations  of anti-DNP  and  of  anti-OVA  antibodies  to  total  serum gamma 
globulins  occurred  in  these  recipients.  A  group  of  control  strain  13  animals 
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FIG. 1.  Stimulation of  antibody production  as a  result  of transfer  of  immunocompetent 
strain 2 cells into primed strain 13 recipients:  In the absence of secondary antigenic challenge. 
200  X  106  strain 2  lymph node and spleen cells were injected  intravenously into strain  13 
recipients primed 3 wk earlier  with DNP-OVA. Recipients were bled at various times after 
cell transfer without a subsequent antigenic challenge and their sara were analyzed for anti- 
DNP  and  anti-OVA antibody  and  total  gamma globulin  concentrations.  The  numbers  in 
parentheses refer to the number of recipients analyzed at a given time after transfer. 
which had been primed with DNP-OVA but which had not received any strain 
2 lymphoid cells showed no change in anti-DNP antibody concentration during 
this time. 
The effect of secondary  antigen  challenge with a DNP-heterologous  carrier: Al- 
though  the marked rises in serum anti-DNP  and  anti-OVA antibody concen- 
trations  described  above  occurred  without  secondary  antigenic  challenge, 
such a  secondary challenge  administered  at various times after transfusion  of 
allogeneic  cells  had  a  considerable  effect on  anti-DNP  antibody  levels.  Re- 
cipients challenged with  1.0  mg of DNP-BGG 6  days  after cell transfer dis- 
played serum anti-DNP  antibody concentrations  7  days later  (13  days after KATZ,  PAUL,  GOIDL,  AND  BENACERRAF  173 
transfer) which were strikingly higher than those of recipients which were not 
challenged with antigen (Fig. 2).  Furthermore,  contrary to expectations, cells 
from BGG-primed donors were no more effective than cells from CFA-primed 
donors in preparing recipients for an anti-DNP response to the secondary chal- 
lenge with DNP-BGG.  Thus,  as a  result of the  transfer  of allogeneic cells, a 
considerable secondary anti-DNP  response  to  DNP-BGG  could be  obtained 
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FIG. 2.  Stimulation of anti-DNP antibody production as a result of transfer of immuno- 
competent strain 2 cells into primed strain 13 recipients: The effect of secondary antigenic 
challenge with a DNP-heterologous conjugate 6 days after transfer. 200 X  106 strain 2 lymph 
node and spleen  (CFA or BGG) cells were injected intravenously into strain 13 recipients 
primed 3 wk earlier with DNP-OVA.  Recipients were  either not boosted  or boosted  with 
I)NP-BGG 6 days after transfer. The number in parentheses refer to the number of recipients 
in a given group.  The left panel illustrates the anti-DNP responses  of recipients of CFA 
cells, while the right panel illustrates the anti-DNP responses of recipients  of BGG-specific 
cells. 
in  animals primed  to  DNP-OVA.  This  allogeneic effect  therefore  appears  to 
remove the need for the action of BGG-specific carrier cells in the secondary 
response  to  DNP-BGG.  Thus  far,  attempts  to  achieve  augmented  primary 
anti-DNP  antibody responses  to DNP-BGG  in  animals which  have  received 
allogeneic lymphoid cells have failed. 
When DNP-OVA-primed strain 13 guinea pigs which had received 200 X  106 
lymph node and spleen cells from strain 2 animals were challenged with DNP- 
BGG soon  (1  or 3  days)  or later  (13  days)  after cell transfer,  the  anti-DNP 
antibody response was  totally different from that of similar guinea pigs chal- Ld 
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Fie. 3.  Stimulation of anti-DNP antibody production as a result of transfer of immuno- 
competent strain 2 cells into primed strain 13 recipients: The effect of secondary  antigenic 
challenge with a  DNP-heterologous conjugate at  various times after transfer. 200  X  106 
strain 2 lymph node and spleen (CFA or BGG) cells were injected intravenously into strain 13 
recipients primed 3  wk  earlier with DNP-OVA.  The  top  panel illustrates the anti-DNP 
responses of nonboosted recipients, of recipients of BGG cells which were boosted with DNP- 
BGG  1 day after transfer, and of recipients of CFA cells which were boosted with DNP- 
BGG 3 days after transfer. The lower left panel illustrates the anti-DNP responses of non- 
boosted recipients and of recipients of BGG or CFA cells which were  boosted 6 days after 
transfer. The lower right panel illustrates the  anti-DNP responses of nonboosted recipients 
and of recipients of BGG or CFA cells boosted 13 days after transfer. Numbers in parentheses 
refer to the numbers of recipients in a given group. 
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lenged at 6 days after cell transfer. Fig. 3 illustrates the results of these studies. 
In the three panels of this figure, the effects of challenge with DNP-BGG at 
days 1 and 3, day 6, and day 13, respectively, after cell transfer are compared, 
using as a reference the anti-DNP serum concentrations in animals not chal- 
lenged, illustrated also in Fig. 1. 
Animals challenged with DNP-BGG 1 day after transfer have lower serum 
anti-DNP  antibody concentrations  than  do nonchallenged  animals.  Indeed, 
the challenged animals display an initial fall in anti-DNP antibody concentra- 
tion.  The concentration is  still below  that  before challenge at  7  days  after 
challenge, and at 11 days after challenge it is only slightly greater than that 
before challenge.  In those animals challenged 3  days  after transfer,  there  is 
also an initial fall in serum anti-DNP antibody concentration. There is, how- 
ever, a relatively rapid recovery so that serum anti-DNP antibody levels are 
greater than in animals challenged  1 day after transfer, but these levels are 
still less  than  those of nonchallenged animals.  Challenge with DNP-BGG 6 
days after allogeneic cell transfer produced a marked enhancement in serum 
anti-DNP  antibody  concentrations,  compared  to  nonchallenged  animals  as 
described above. Challenge 13 days after cell transfer failed to cause an aug- 
mentation of serum anti-DNP antibody levels. 
Thus, a  crucial relationship must be maintained between time of antigenic 
challenge and of allogeneic cell transfer to facilitate stimulation of secondary 
anti-DNP  responses by a  DNP-heterologous protein  conjugate in  recipients 
of allogeneic cells. 
Demonstration of the Allogeneic Effect  in  Strain  2  Recipients  of Strain  13 
Cells.--The  previous  experiments have  demonstrated  the  occurrence of  the 
allogeneic effect when  cells  of  strain  2  origin  were  transferred  to  strain  13 
recipients. That the phenomenon results from allogeneic differences between 
cells of donor and host origin and is not related to properties unique to strain 
13  recipients was  confirmed by the demonstration of the same  effect in  the 
reciprocal transfer protocol, i.e., where donor cells were obtained from strain 
13 guinea pigs and transferred to strain 2 recipients. Both syngeneic combina- 
tions (i.e. strain 13 to strain 13 and strain 2 to strain 2) were included in this 
study as further controls. The same general protocol as described in the previous 
experiments was followed. All recipients were boosted with DNP-BGG 6 days 
after transfer. Bleedings were performed on the day of boosting and 4  and 7 
days later. 
The results are presented in Table I. Recipients of 200 X  l0 s allogeneic BGG 
or CFA cells (groups A and B, respectively) manifested a striking rise in anti- 
DNP antibody levels between days 6 and 13 after transfer. The effect could be 
observed as early as day 10 (4 days after challenge) in contrast to the situation 
in syngeneic combinations which usually do not manifest a rise in anti-DNP 
levels  until  day  13  after  transfer  of  carrier-specific cells.  Furthermore,  the 176  STIMULATION OF  2 °  ANTIBODY  SYNTHESIS  BY  G-V-H  RX 
magnitude of the peak anti-DNP response in the allogeneic transfer system is 
greater than that obtained in strain 2 recipients of 1000 X  106 syngeneic carrier- 
specific cells (5). The responses observed in the strain 13 and strain 2 syngeneic 
combinations after  transfer  of 200  X  106  cells from BGG-primed donors  are 
shown  in Table I  by groups  C  and D,  respectively. The response in both  in- 
stances is poor by day 13; however, a  clear enhancement was observed by day 
17  (not shown),  although  it was  not  of  the magnitude  seen in the  allogeneic 
combinations. 
TA_BLE I 
Elicitation of the Allogeneic Effect in DNP-OVA-Primed Strain  2 Guinea Pigs after Passive 
Transfer oj" Strain  13 Guinea Pig Lymph Node and Spleen Cells 
Group 
Protocol*  Anti-DNP antibody ~g/ml)~ 
Day after transfer 
Type of donor cells  Number of 
transferred  recipients  Day 6  Day 10  Day 13  Boost 
A  Strain 13, BGG  5 Strain 2  1.2  13.5  106.1  104.8 
B  Strain 13, CFA  4 Strain 2  1.6  18.7  161.5  160.0 
C  Strain 13, BGG  10 Strain 13  26.9  6.1  12.8  --14.1 
D  Strain  2, BGG  5 Strain 2  0.81  0.20  4.8  4.0 
* 200 X  106 donor lymph node and spleen cells were transferred to individual recipients 
which  had been  immunized  3 wk earlier with DNPT-OVA. Recipients were  boosted  with 
DNP-BGG 6 days after transfer. 
:~ The data are expressed as geometric means. Boost represents the increase in mean anti- 
body levels from the day of boosting  (day 6 after transfer) to 7 days later (day 13). A com- 
parison of the geometric mean anti-DNP serum antibody concentrations on day 13 gave the 
following results: Comparison of group A with group B yielded a P value of 0.50 >  P  >  0.40. 
Comparison  of group A with groups C and D and, similarly, group B with groups C and D 
yielded P values of 0.005 >  P  >  0.001 in each case. 
Effect of Varying Numbers  of Transferred Allogeneic  Cells.--The preparation 
of DNP-OVA-primed  strain  13  animals for a  secondary anti-DNP  antibody 
response  to  DNP-BGG  can  be  achieved  by  the  transfer  of  relatively small 
numbers of strain 2 lymph node and spleen cells. Thus, while transfer of 10  X 
l0 G allogeneic cells failed to  prepare for  a  measurable  response  7  days  after 
challenge (13 days after transfer), 50  X  106 cells stimulated a  clear increase in 
anti-DNP  antibody concentration  at that time  (Table II). Increase of trans- 
ferred cell numbers  to 200  X  106  (4-fold) resulted in a  secondary response of 
approximately 6-fold greater magnitude than had occurred when 50 X  106 cells 
were  transferred.  A  further  3-fold increment in  response was  noted  after  the 
transfer of 1000  X  106 allogeneic cells. 
Effect  of  Presensitization  of Strain  13  Recipients  with  Strain  2  Cells.--The 
participation of living allogeneic cells in at least certain phases of this response 
is well demonstrated by the fact that DNP-OVA-primed strain  13  recipients KATZ~  PAUL~  GOIDL,  AND  BENACERRAF  177 
which have been preimmunized with  the  transplantable  leukemia L2C,  which 
arose in strain 2 guinea pigs (13), do not exhibit any increase in anti-DNP anti- 
body synthesis after allogeneic strain 2 cell transfer. As part of the experiment 
described in the preceding section, 20 strain  13  animals were inoculated intra- 
peritoneally  with  107  live  L~C  cells  (kindly  provided  by  Doctors  Leonard 
Ellman  and  Ira  Green)  15  days  after  they had been primed with DNPT-OVA. 
TABLE II 
Relationship of Cell Number to Magnitude of Allogeneic Effect and Abolition of the Effect in 
Recipients Presensitized with Alto eneic Cells 
Protocol*  Anti-DNP antibody (ug/ml)$ 
Group  Specificity  Day after transfer 
cells 
BGG 
BGG 
BGG 
CFA 
BGG 
BGG 
BGG 
A 
B 
C 
D 
E 
F 
G 
Number 
of cells 
transferred 
1000 X  106 
200 X  106 
50 X  106 
50 ×  106 
10 X  106 
200 X  106 
50 ×  106 
Strain 13 recipients 
Nonsensitized 
Nonsensitized 
Nonsensitized 
Nonsensitized 
Nonsensitized 
Sensitized 
Sensitized 
Num- 
ber of 
recip- 
ients 
5 
5 
5 
5 
4 
10 
10 
Day 6  Day 10  Day 13 
7.9  245.4  1809.2 
6.6  I 105.7  552.0 
9.6  11.6  95.4 
16.7  18.1  48.8 
11.3  0.62  2.0 
18.7  5.7  8.6 
22.8  7.2  11.5 
Boost 
1801.3 
545.4 
85.8 
32.1 
--9.3 
--10.1 
--11.3 
* 10 )<  106 to 1000 X  106 strain 2 lymph node and spleen cells were transferred  to indi- 
vidual strain  13 recipients which had been immunized 3 wk earlier with DNP~-OVA. Sensi- 
tized recipients  (groups F and  G) had  received 107 strain  2 leukemia cells intraperitoneally 
7 days before cell transfer. All recipients were boosted with DNP-BGG 6 days after transfer. 
:~ The data are expressed as geometric means. Boost represents  the increase in mean anti- 
body levels from the day of boosting  (day 6 after transfer)  to 7 days later (day  13). A com- 
parison of the geometric mean anti-DNP serum antibody  concentrations  on day 13 gave the 
following results:  Comparison  of groups A and  B yielded  a  P  value  of 0.10 >  _P  >  0.05. 
Comparison  of group A with groups C and  D yielded _P values of 0.005  >  P  >  0.001  in 
each case. Comparison of group B with groups C and D also yielded P  values of 0.005 >  P  > 
0.001 in each case. Comparisons of group B with group F and group C with group G yielded 
P values of P  <  0.001 in both cases. 
7 days later either 50 or 200  X  106 strain 2 lymph node and spleen cells were 
transferred  to  these  recipients  and  6  days  later  they  were  challenged  with 
DNP-BGG.  Neither  group  demonstrated  an  increase  in  serum  anti-DNP 
antibody levels over the next 7  days,  which  is in marked  contrast  to  similar 
recipients which had not been previously inoculated with  the L2C cells (Table 
II).  Thus,  presensitization  to  cells  bearing  strain-specific  histocompatibility 
antigens  2 abrogates the allogeneic effect. 
Relative  Response  to  DNP-BGG Challenge  of DNP-OVA-Primed  Syngeneic 
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Strain 2 and Allogeneic Strain 13 Recipients  of Strain 2 Lymphoid Cells from 
BGG-Sensitized  Donors.--The magnitude of the allogeneic effect demonstrated 
in  these studies  is  considerable. Indeed,  the  effectiveness of BGG-sensitized 
strain 2 cells to prepare for a secondary anti-DNP response is strikingly greater 
in strain 13 recipients than in strain 2 recipients when both groups are challenged 
with I)NP-BGG 6 days after transfer. Thus, Fig. 4 compares the responses of 
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FIO. 4.  Relative response to DNP-BGG challenge of DNP-OVA-primed strain 2 syngeneic 
and strain 13 allogeneic recipients of strain 2  lymphoid  cells from BGG-sensitized donors. 
1 X  10  s lymph node and spleen cells from BGG-sensitized strain 2 donors were transferred to 
strain 2  and strain 13  recipients primed with DNP-OVA 3  wk  earlier. All recipients were 
boosted with DNP-BGG  6  days  after transfer.  Serum anti-DNP  antibody concentrations 
just before challenge and on days 4 and 7 after challenge are illustrated in the large panel. The 
far right panel illustrates the serum anti-B GG antibody concentrations just before and 7 days 
after challenge. The numbers in parentheses refer to the numbers of recipients in the given 
groups. 
strain 2 and strain 13 recipients of 1000 X  106 BGG-sensitized strain 2 lymph 
node and spleen cells to challenge with DNP-BGG. A response in the allogeneic 
recipients is already apparent on day 4  after challenge; on day 7,  the serum 
anti-DNP  concentration is  170-fold greater than it was  before challenge. In 
contrast, the syngeneic (strain 2)  recipients do not demonstrate a measurable 
response 4  days after challenge, and on day 7 the anti-DNP level is  70-fold 
greater than it was just before challenge. Again, however, in the interpretation 
of responses in  the  allogeneic system,  the  fact that  a  considerable  response 
occurs without antigen challenge must be taken into account. KATZ,  PAUL~  GO1DL,  AND  BENACERRAF  179 
Although the anti-DNP response in strain  13 recipients of cells from BGG- 
primed strain 2 guinea pigs is greater than is the anti-DNP response of strain 
2 recipients, the reverse is true of the anti-BGG responses. Anti-BGG antibodies 
are not detected  (P~0 <  5/zg/ml) either before DNP-BGG challenge or 7 days 
later in the allogeneic recipients,  whereas they are measurable before challenge 
in the syngeneic recipients and their concentration increases 7 days later. This 
suggests that the allogeneic effect does not require the active participation  of 
immunoglobulin-secreting donor cells, at least at the time of antigenic challenge. 
TABLE III 
Capacities of Nonirradiated  and  Irradiated  Lymph  Node  and  Spleen  Cells, Leukemia  Cells 
and Normal Spleen Cells from Strain g Guinea Pigs to Elicit the Allogeneie Effect in 
Strain 13 Recipients 
Group 
A 
B 
C 
D 
E 
Protocol* 
Tyt e of strain 2 donor cells 
transferred 
k-nonirradiated 
k-nonirradiated 
k-irradiated, 3000 R 
Strain 2 leukemia 
mal spleen cells 
Secondary 
immunization 
l~um- 
ber of 
recip- 
ients 
DNPe3-BGG  5 
None  5 
DNP2a-BGG  5 
DNP23-BGG  5 
DNP23-BGG  4 
Anti-DNP antibody ~g/ml)$ 
Day after transfer 
Boost  Day 6 
9.5 
11.6 
33.8 
27.4 
10.1 
D  ayl0  Day 13_ 
202.2  435.4 
169.11 197.8 
4.71  5,8 
2.81  4.3 
27.5 /  74.0 
425.9 
186.2 
--28.0 
--23.1 
63.9 
* 200 X  106 strain  2 guinea pig donor cells, of the types indicated,  were transferred  to 
strain  13 recipients which had been immunized 3 wk earlier with  DNPT-OVA. Recipients 
were boosted 6 days after transfer with DNP-BGG. 
The data are expressed as geometric means. Boost represents the increase in mean anti- 
body levels from the day of boosting  (day 6 after transfer) to 7 days later (day 13). A com- 
parison of the geometric mean anti-DNP serum antibody concentrations  on day 13 gave the 
following results: Comparison of group A with groups C, D, and E yielded P values of <  0.001 
in each case. Comparison of group B with groups C, D, and E yielded _P values of <0.001, 
<  0.001, and 0.10 >  0.05, respectively. Comparison of group A with group B yielded a P 
value of 0.02 >  P  >  0.01. 
Graft-versus-Host Reaction  as  the  Mechanism  of  the  Allogeneic  Effect.--Two 
possible  mechanisms  by  which  allogeneic  cells  may  exert  their  function  in 
recipients  are  (a) by acting as targets for a  host-versus-graft response and  (b) 
by acting as effectors of a graft-versus-host response. In order to choose between 
these two possibilities,  we studied the capacity of irradiated strain 2 lymphoid 
cells,  of strain  2  leukemia  cells,  and  of  (2  X  13)F1 hybrid  lymphoid cells  to 
mediate the allogeneic effect in DNP-OVA-primed strain 13 recipients. 
Table  III  demonstrates  that  3000  R  administered  in  vitro  completely- 
abolishes  the  capacity  of  lymph  node  and  spleen  cells  from strain  2  guinea 
pigs  to prepare  I)NP-OVA-primed  strain  13  recipients  for  a  secondary  re- 180  STIMULATION  OF  2 °  ANTIBODY  SYNTHESIS  BY  G-V-It  RX 
sponse to  DNP-BGG.  This  is  of  particular  interest because  the  capacity  of 
syngeneic BGG-primed  lymphoid  cells  to prepare for  such a  response has pre- 
viously been  shown  not  to be  diminished  by  in  vitro  irradiation  with  doses 
TABLE  IV 
Capacities  of Nonirradiated  and  Irradiated  Strain 2 BGG and  CFA  Cells, and  (2)~  13)  F1 
Hybrid Lymph Node and Spleen  Calls to Elicit the Allogeneic Effect in Strain 13 Recipients 
Protocol* 
Group 
A 
B 
C 
D 
E 
F 
G 
Type of cells transferred 
Strain 2  BGG  cells,  non- 
irradiated 
Strain 2  BGG cells,  non- 
irradiated 
Strain  2  CFA  cells,  non- 
irradiated 
Strain 2 BGG ceils, irradi- 
t 
Anti-DNP antibody (~/ml)~: 
Num-  /  Day after transfer 
Secondary  ber of I 
immunization  recip-  .... 
ients  Day 6  Day 10  Day 13  Boost 
DNP-BGG  [  4  ]  9.1  17.3  205.2  196.1 
None  4  6.7  61.7  104.1  97.4 
DNP-BGG  5  3.6  i 34.0  163.8  160.2 
DNP-BGG  4  2.2  0.12  1.2  --1.0 
ated-3000 R 
Strain 2 BGG cells, irradi- 
ated-3000 R 
Strain 2 CFA cells,  irradi- 
ated-3000 R 
(2 X  13) F~ hybrid CFA 
cells,  nonirradiated 
None 
DNP-BGG 
DNP-BGG 
4.0  3.8 
7.5  0.56 
9.7  0.75 
3.6 
1.7 
2.7 
i 
--0.4 
--5.8 
--7.0 
* 200  X  106 donor cells,  of the type indicated, were transferred to strain 13 recipients 
which had been immunized 3 wk earlier with DNPT-OVA.  Recipients were boosted 6  days 
after transfer with DNP-BGG. 
:~ The data  are  expressed  as  geometric  means.  Boost  represents the  increase in mean 
antibody levels from the day of boosting (day 6 after transfer) to 7 days later (day 13).  A 
comparison of the geometric mean anti-DNP serum antibody concentrations on day 13 gave 
the following results: Comparison of group A with groups B and C yielded P  values of 0.30 > 
P  >  0.20 and 0.80  >  P  >  0.70, respectively. Comparison of group A with groups D  and G 
yielded P  values of P  <  0.001  and 0.005  >  P  >  0.001  respectively. Comparison of group B 
with groups D  and E  yielded P  values of P  <  0.001  and 0.005  >  P  >  0.001, respectively. 
Comparison of group B with group G yielded a P  value of 0.01  >  P  >  0.005. Comparison of 
group C with groups F and G yielded P  values of P  <  0.001  and 0.01  >  P  >  0.005, respec- 
tively. 
as  high  as  5000  R  (10).  The  allogeneic  and syngeneic transfers appear there- 
fore  to  utilize  separate  mechanisms  for  the  stimulation of the recipients' pre- 
cursors of antibody-forming cells. 
Furthermore,  L2C strain 2  leukemia  cells fail to prepare DNP-OVA-primed 
strain  13  guinea  pigs  for  an  anti-DNP  response  to  DNP-BGG.  These  two 
experiments  therefore  suggest  that  immunocompetent,  radiation-sensitive KATZ, PAUL, GOIDL, AND BENACERRAF  181 
cells  are  required for the expression of the allogeneic effect. In addition,  as 
shown in Table III, 200  X  106 spleen ceils from normal strain 2 donors are 
inferior to an equal number of lymph node and spleen cells from CFA-primed 
strain 2 donors in mediating the allogeneic effect. This suggests that a  sub- 
population of lymphoid cells more numerous in lymph node than in  spleen is 
involved in the response. 
Table IV presents results from another experiment in which the radiation 
sensitivity of the allogeneic effect is  clearly demonstrated. The data further 
show that both the response which depends on antigen challenge and the one 
which is  independent of such  challenge are  equally inhibited  as  a  result  of 
in vitro irradiation of donor lymphocytes. 
Finally, in the experiment illustrated by Table IV,  transfer of 200  X  106 
(2)<  13)F1 hybrid lymph node and  spleen  ceils  from CFA-primed  animals 
failed  to  prepare  DNP-OVA-primed  strain  13  recipients  for  an  anti-DNP 
response to DNP-BGG. Thus, not only must the transferred cells be immuno- 
competent, they must also have the genetically-determined capacity to respond 
to the histocompatibility antigens of the recipient. These experiments, taken 
together, provide strong evidence that the allogeneic effect observed here is 
mediated through the immunologic attack of graft cells on host cells. It should 
also be  noted  that in  those cases  in  which  the  allogeneic effect was  noted, 
recipients  displayed enlarged  spleens.  The  latter  is  a  regular  occurrence  in 
graft-versus-host  reactions. 
DISCUSSION 
A considerable body of evidence  now exists which demonstrates that two 
independent lymphoid cell populations participate, in a specific way, in anti- 
body responses. Cell interactions have been described, thus far, in humoral 
immune responses to foreign erythrocyte antigens (14-16), proteins (17, 18), 
and hapten-protein conjugates (4-8). In the study of responses to the latter 
class of antigens, it has become  clear  that the participating cells  may be specific 
for different  determinants on the immunogen and that the two cell types may 
display a different  range of effective  specificity  (5, 8, 19). 
Of the cell types involved, one appears to be the direct precursor of anti- 
body-forming cells and to possess receptors  with specificity  identical with that 
of the antibody to be secreted by its progeny. The other cell fails to secrete 
detectable amounts of antibody, but nevertheless  plays a role in the activation 
of the precursor described above (3, 20, 21). In the mouse, this "helper" cell 
has been demonstrated to be thymus-derived and  to bear the isoantigen 0 
(8, 22). The receptors  possessed by this cell t~e appear not to recognize  many 
haptenic determinants, or members  of this cell  type with highly  hapten-specific 
receptors  are rare. This  involvement  of two cell  types and their distinct specific- 
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ity of secondary anti-hapten antibody responses which was discussed in  the 
introduction. Experiments have demonstrated that the transfusion of lymph 
node and spleen cells from BGG-immune donors into syngeneic DNP-OVA- 
primed recipients prepares  the  latter for a  secondary anti-DNP  response  to 
DNP-BGG (5). 
Two new phenomena which result from the transfer of allogeneic cells and 
the subsequent development of graft-versus-host reactions in recipients primed 
with a  hapten-protein  conjugate have been  described in  the present study: 
(a)  The  considerable  stimulation  of  anti-hapten  and  anti-carrier  antibody 
synthesis in the absence of any new exogenous antigenic challenge.  (b)  The 
heightened  capacity  of  animals  undergoing  a  graft-versus-host  reaction  to 
develop  secondary anti-hapten  antibody responses  to  hapten  heterologous- 
carrier conjugates. 
Thus,  DNP-OVA-primed  allogeneic  recipients  were  shown  to  synthesize 
considerable  amounts  of  both  anti-DNP  and  anti-OVA  antibody  without 
secondary challenge. The relative magnitude of increase in serum anti-DNP 
and  anti-OVA  antibody concentrations was much  greater  than  that  of  the 
increase in serum immunoglobulin concentration. This suggests that the acti- 
vation of precursors of antibody-forming cells has a degree of selectivity. Such 
a  selectivity could be explained either by a particular sensitivity of immuno- 
competent cells at a certain stage of differentiation (e.g. those relatively recently 
stimulated  by  primary  immunization)  to  the  effect of  allogeneic  cells,  or 
alternatively, by an  increase  in  the  sensitivity of memory cells  to  residual 
antigen as a result of the graft -versus-host reaction. 
In addition to the spontaneous synthesis of both anti-DNP and anti-OVA 
antibody in the absence of antigenic challenge, a  considerable anti-DNP  re- 
sponse  ensues  to  immunization with  DNP-BGG.  This  latter  effect in  the 
allogeneic transfer system is,  however,  rather different from that previously 
described in syngeneic transfer systems. In the syngeneic transfer, preparation 
for secondary response is dependent on the specificity of the transferred cells. 
Cells from BGG-primed donors prepare the recipient for a secondary anti-DNP 
response to DNP-BGG; cells from CFA-primed donors have no effect (5). In the 
allogeneic transfer, cells from BGG-prilned and from CFA-primed donors are 
equal in efficiency in preparing for a  secondary anti-DNP response to DNP- 
BGG. In the syngeneic system, the effectiveness of carrier-specific  donor cells 
is preserved after in vitro exposure to as much as 5000 R of X-irradiation (10), 
whereas 3000 R  completely prevents allogeneic cells from exerting their effect 
upon transfer. 
These  differences point  to  a  distinction in  the  mechanism by which  the 
transferred cells function in the two situations. It seems most likely that in the 
syngeneic transfer of cells from BGG-primed donors the transferred cells  act 
in a way similar to the normal, physiologic action of autologous helper cells in 
the activation of precursors of antibody-forming cells. The establishment of the KATZ,  PAUL,  GOIDL,  AND  BENACERRAF  183 
nature of this action is one of the key goals of current research work in cellular 
immunology. The evidence presented in the current paper indicates that the 
allogeneic cells function by virtue of a specific immtmologic attack of grafted 
cells on host cells.  This is concluded on the basis  of the following evidence: 
L2C leukemia cells,  which bear strain  2 histocompatibility antigens,  2 fail to 
prepare  DNP-OVA-primed  strain  13  recipients  for  a  secondary  anti-DNP 
response to DNP-BGG; similarly, irradiated strain 2 lymph node and spleen 
cells are without effect. In both instances, the transferred cells, although lacking 
the ability to mediate graft-versus-host  responses,  are capable of initiating  a 
host-versus-graft  response. The failure of these cells to mediate the allogeneic 
effect therefore indicates that the rejection of donor cells by the host is not the 
crucial  event.  Indeed,  if  the  host  is  presensitized  to  donor  transplantation 
antigens, as in the transfer of strain 2 cells into a DNP-OVA-primed strain 13 
recipient which has been preimmunized with the L~C leukemia, the allogeneic 
effect is completely abolished. On the other hand, the notion that a graft-versus- 
host response, or one of its components, is involved is strongly supported by 
the failure of (2  X  13)F1 hybrid lymph node and spleen cells to mediate the 
allogeneic  effect in  DNP-OVA-primed  strain  13  recipients.  These  cells  are 
normal immunocompetent cells but lack the capacity to recognize strain  13 
histocompatibility antigens as foreign by virtue of their genetic constitution. 
Further,  supportive evidence that  the  allogeneic effect is  related to a  graft- 
versus-host  phenomenon is provided by the considerable superiority of lymph 
node-spleen  cell mixtures  over spleen  cells  in  mediating  the  response.  This 
indicates that lymph node cells are superior to spleen cells and is in accord with 
the demonstration by Cantor, Mandel,  and Asofsky (23)  that, in the mouse, 
fewer lymph node cells than spleen cells are required to obtain a given spleen 
index in the Simonsen assay of the graft-versus-host  reaction. 
Howard  and Woodruff (24)  have shown  that  in  adult  immunocompetent 
mice undergoing a  graft-versus-host  response, primary antibody responses to 
the H  antigen of Salmonella  typhi were less  than normal. They examined the 
response  14-19  days after cell transfer.  In  our studies,  there was a  striking 
difference in the outcome of antigenic challenge as the temporal relation between 
challenge and  allogeneic cell transfer was  varied.  Thus,  when challenge was 
carried out 13 days after transfer, no effect was noted; challenge at 6 days led 
to a marked augmentation, whereas challenge 1 or 3 days after transfer resulted 
in  a  depression  of  anti-DNP  antibody concentrations  as  compared to  non- 
challenged  recipients. This time dependence suggests  that  a  precise relation 
exists between attack of transferred cells on host cells and antigenic stimulation 
of such cells.  When antigenic challenge is administered 1 day after allogeneic 
cell transfer,  the serum anti-DNP  antibody concentrations are markedly de- 
pressed when compared with those of a nonchallenged animal. This may be the 
consequence either  of  transferred  antigen  binding  synthesized antibody and 
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differentiation of precursors of antibody-forming cells. That is, an initial inter- 
action of DNP-BGG, for which very few helpers would be present, with pre- 
cursors of anti-DNP  antibody-synthesizing cells  may render the cells  insensi- 
tive to the subsequent stilnulatory effect of allogeneic cells. 
The effectiveness of antigenic challenge 6 days after cell transfer, which is at 
a time when the graft-versus-host reaction or its immediate consequences might 
be quite intense, would suggest that the stimulation either of helper cells or of 
precursors of antibody-producing cells by antigen is markedly enhanced directly 
or by the release of adjuvant factors as a result of the immunologic attack of 
graft cells.  The data described thus far do not allow a decision as to which of 
these two cell classes constitutes the relevant target cell for the expression of 
the allogeneic effect nor as to the mechanism of the effect. Further, an evalua- 
tion must still be made of what  the nature of the  effector allogeneic cell is. 
Cantor and Asofsky (25)  have recently demonstrated a cooperative lymphoid 
cell interaction in graft-versus-host  reactions in mice. They propose an inter- 
action  between  two  thymus-derived lymphocytes in  which  one cell initially 
encounters antigen and the second cell is responsible for the pathogenic aspects 
of the phenomenon. Which of these two cell types is effective in the allogeneic 
effect under study here is not known. Antibody-secreting cells of the donor are, 
however,  unlikely  to  be  important  participants  in  this  phenomenon.  Thus, 
anti-BGG  antibody,  which  is  being  produced by the  transferred cells  when 
they  are  placed  in  a  syngeneic host,  cannot  be  detected  in  the  allogeneic 
recipient. This finding would be expected on the basis of the studies of ~terzl 
and Trnka (26) who demonstrated that antibody-producing cells are eliminated 
quite rapidly after transfer to immunocompetent allogeneic or xenogeneic hosts. 
It  seems  likely that  the  activation  of  the  precursors  of  antibody-forming 
cells,  particularly  when  no  exogenous secondary antigenic  challenge  is  ad- 
ministered,  proceeds by a  mechanism  akin  to  the proliferation of host bone 
marrow-derived cells which is largely responsible for the splenomegaly observed 
in the graft-~Jersus-host response. Whether the effect of DNP-BGG in this case 
is directly upon DNP-specific precursors of antibody-forming cells or on helper 
cells has  not  been  established.  It  is  nevertheless  tempting  to  consider  that 
precursors of antibody-forming cells  which are already receiving one type of 
stimulus (i.e. that resulting, directly or indirectly, from the attack of allogeneic 
cells)  might be especially sensitive to antigenic stimulus. Under these circum- 
itances, an initial interaction of antigen with carrier specific helper cells might 
be unnecessary. In turn, an evaluation of the details of this phenomenon may 
well  provide  insight  into  ~he  normal  stimuli  which  activate  precursors  of 
antibody-forming cells. 
SUMMARY 
The  studies  reported  here  demonstrate  that  immunocompetent  lymphoid 
cells from allogeneic donor guinea pigs  stimulate  the synthesis of anti-DNP KATZ, PAUL, GOIDL, AND BENACERRAF  185 
and  anti-OVA  antibodies  by  recipients  previously primed  with  DNP-OVA. 
This allogeneic effect occurs spontaneously in the absence of any further anti- 
genic  challenge.  Furthermore,  the  transfer  of allogeneic cells prepares DNP- 
OVA-primed recipients for a  striking secondary anti-DNP response to DNP- 
BGG; this  occurs in  equal degree whether  or not  the  cells  are derived  from 
BGG-primed donors. We suggest that the allogeneic cells function by virtue of 
a  specific immunologic attack of grafted cells on host cells. This conclusion is 
made on the basis of the following evidence:  (a) The failure of observing the 
phenomenon with L2C leukemia cells and irradiated strain 2 lymph node and 
spleen cells which,  although capable of initiating  a host-versus-graft response, 
are incapable of mediating graft-versus-host reactions; and  (b)  the inability of 
(strain  2  X  strain  13)F1  hybrids to mediate the allogeneic effect in strain  13 
recipients. The analysis of this phenomenon may offer a key to the delineation 
of mechanisms involved in  the  activation  of precursors  of  antibody-forming 
cells. 
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